These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Sonis S; Treister N; Chawla S; Demetri G; Haluska F Cancer; 2010 Jan; 116(1):210-5. PubMed ID: 19862817 [TBL] [Abstract][Full Text] [Related]
3. Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors. Pilotte AP; Hohos MB; Polson KM; Huftalen TM; Treister N Clin J Oncol Nurs; 2011 Oct; 15(5):E83-9. PubMed ID: 21951751 [TBL] [Abstract][Full Text] [Related]
4. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors. De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963 [TBL] [Abstract][Full Text] [Related]
5. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Martins F; de Oliveira MA; Wang Q; Sonis S; Gallottini M; George S; Treister N Oral Oncol; 2013 Apr; 49(4):293-8. PubMed ID: 23312237 [TBL] [Abstract][Full Text] [Related]
6. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. Chambers MS; Rugo HS; Litton JK; Meiller TF J Am Dent Assoc; 2018 Apr; 149(4):291-298. PubMed ID: 29439772 [TBL] [Abstract][Full Text] [Related]
7. Clinical presentation and management of mTOR inhibitor-associated stomatitis. de Oliveira MA; Martins E Martins F; Wang Q; Sonis S; Demetri G; George S; Butrynski J; Treister NS Oral Oncol; 2011 Oct; 47(10):998-1003. PubMed ID: 21890398 [TBL] [Abstract][Full Text] [Related]
16. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients. Lo Muzio L; Arena C; Troiano G; Villa A Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626 [TBL] [Abstract][Full Text] [Related]
17. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Vigarios E; Epstein JB; Sibaud V Support Care Cancer; 2017 May; 25(5):1713-1739. PubMed ID: 28224235 [TBL] [Abstract][Full Text] [Related]
18. Adverse events associated with mTOR inhibitors. Pallet N; Legendre C Expert Opin Drug Saf; 2013 Mar; 12(2):177-86. PubMed ID: 23252795 [TBL] [Abstract][Full Text] [Related]
19. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor. Peuvrel L; Quéreux G; Brocard A; Saint-Jean M; Dréno B Dermatology; 2012; 224(3):204-8. PubMed ID: 22614575 [TBL] [Abstract][Full Text] [Related]
20. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Nicolatou-Galitis O; Nikolaidi A; Athanassiadis I; Papadopoulou E; Sonis S Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Aug; 116(2):e110-6. PubMed ID: 23643584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]